{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T04:12:28Z","timestamp":1742530348043,"version":"3.40.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015993","name":"Kowa Company Ltd","doi-asserted-by":"publisher","award":["20-P06"],"award-info":[{"award-number":["20-P06"]}],"id":[{"id":"10.13039\/100015993","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology Cardiovascular Risk and Prevention"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ijcrp.2024.200359","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T07:58:17Z","timestamp":1734076697000},"page":"200359","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Evaluation of the beneficial effects of pemafibrate in hypertriglyceridemia with or without alcohol drinking (PAR-CHAT: PARmodia-CHikushi Anti-dyslipidemia Trial)"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6439-8528","authenticated-orcid":false,"given":"Yosuke","family":"Takamiya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiyori","family":"Imanaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amane","family":"Ike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenori","family":"Urata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.ijcrp.2024.200359_bib1","first-page":"51s","article-title":"Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults--the evidence report. National Institutes of Health","volume":"6","year":"1998","journal-title":"Obes. Res."},{"issue":"Suppl 3","key":"10.1016\/j.ijcrp.2024.200359_bib2","first-page":"32","article-title":"Dyslipidaemia in diabetes mellitus. Review of the main lipoprotein abnormalities and their consequences on the development of atherogenesis","volume":"25","author":"Verg\u00e8s","year":"1999","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.ijcrp.2024.200359_bib3","doi-asserted-by":"crossref","first-page":"67U","DOI":"10.1016\/S0002-9149(98)00848-0","article-title":"Diabetic dyslipidemia","volume":"82","author":"Kreisberg","year":"1998","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcrp.2024.200359_bib4","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jama.298.3.299","article-title":"Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women","volume":"298","author":"Nordestgaard","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.ijcrp.2024.200359_bib5","doi-asserted-by":"crossref","first-page":"846","DOI":"10.5551\/jat.GL2017","article-title":"Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017","volume":"25","author":"Kinoshita","year":"2018","journal-title":"J. Atherosclerosis Thromb."},{"key":"10.1016\/j.ijcrp.2024.200359_bib6","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3132\/dvdr.2008.046","article-title":"The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient","volume":"5","author":"Fruchart","year":"2008","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"10.1016\/j.ijcrp.2024.200359_bib7","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-230X-12-2","article-title":"Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population","volume":"12","author":"Sumida","year":"2012","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.ijcrp.2024.200359_bib8","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/jdi.13306","article-title":"Japanese clinical practice guideline for diabetes 2019","volume":"11","author":"Araki","year":"2020","journal-title":"J. Diabetes Investig."},{"key":"10.1016\/j.ijcrp.2024.200359_bib9","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","article-title":"The Japanese Society of hypertension guidelines for the management of hypertension (JSH 2019)","volume":"42","author":"Umemura","year":"2019","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.ijcrp.2024.200359_bib10","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1530-0277.2008.00827.x","article-title":"Molecular mechanisms of alcoholic fatty liver","volume":"33","author":"Purohit","year":"2009","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.ijcrp.2024.200359_bib11","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1053\/j.gastro.2004.09.049","article-title":"The role of AMP-activated protein kinase in the action of ethanol in the liver","volume":"127","author":"You","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ijcrp.2024.200359_bib12","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1002\/hep.22222","article-title":"Cytochrome P450 2E1 contributes to ethanol-induced fatty liver in mice","volume":"47","author":"Lu","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.ijcrp.2024.200359_bib13","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/apt.16596","article-title":"Randomised clinical trial: pemafibrate, a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1), versus placebo in patients with non-alcoholic fatty liver disease","volume":"54","author":"Nakajima","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ijcrp.2024.200359_bib14","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1111\/hepr.13571","article-title":"Effect of pemafibrate on fatty acid levels and liver enzymes in non-alcoholic fatty liver disease patients with dyslipidemia: a single-arm, pilot study","volume":"50","author":"Seko","year":"2020","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.ijcrp.2024.200359_bib15","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1007\/s12072-022-10453-1","article-title":"Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study","volume":"17","author":"Morishita","year":"2023","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.ijcrp.2024.200359_bib16","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.atherosclerosis.2016.02.029","article-title":"Effects of K-877, a novel selective PPAR\u03b1 modulator (SPPARM\u03b1), in dyslipidaemic patients: a randomized, double blind, active- and placebo-controlled, phase 2 trial","volume":"249","author":"Ishibashi","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijcrp.2024.200359_bib17","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcrp.2024.200359_bib18","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.atherosclerosis.2017.03.032","article-title":"Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1), in combination with statin treatment: two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia","volume":"261","author":"Arai","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijcrp.2024.200359_bib19","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/ATVBAHA.114.303284","article-title":"Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study","volume":"34","author":"Hoogeveen","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ijcrp.2024.200359_bib20","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"41","author":"Bor\u00e9n","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcrp.2024.200359_bib21","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1373\/clinchem.2015.253757","article-title":"Increased remnant cholesterol explains part of residual risk of all-cause mortality in 5414 patients with ischemic heart disease","volume":"62","author":"Jepsen","year":"2016","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ijcrp.2024.200359_bib22","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.amjcard.2010.07.041","article-title":"Pharmacoepidemiology safety study of fibrate and statin concomitant therapy","volume":"106","author":"Enger","year":"2010","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcrp.2024.200359_bib23","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1001\/jama.292.21.2585","article-title":"Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs","volume":"292","author":"Graham","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ijcrp.2024.200359_bib24","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacl.2017.10.006","article-title":"Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor \u03b1 modulator, in patients with dyslipidemia: results from a 24-week, randomized, double blind, active-controlled, phase 3 trial","volume":"12","author":"Ishibashi","year":"2018","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.ijcrp.2024.200359_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2020.04.009","article-title":"The association between triglycerides and incident cardiovascular disease: what is \"optimal\"","volume":"14","author":"Aberra","year":"2020","journal-title":"J. Clin. Lipidol."}],"container-title":["International Journal of Cardiology Cardiovascular Risk and Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772487524001247?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772487524001247?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T16:08:58Z","timestamp":1742486938000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772487524001247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":25,"alternative-id":["S2772487524001247"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcrp.2024.200359","relation":{},"ISSN":["2772-4875"],"issn-type":[{"type":"print","value":"2772-4875"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the beneficial effects of pemafibrate in hypertriglyceridemia with or without alcohol drinking (PAR-CHAT: PARmodia-CHikushi Anti-dyslipidemia Trial)","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology Cardiovascular Risk and Prevention","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcrp.2024.200359","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"200359"}}